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a-Synuclein oligomers are increasingly considered to be responsible for the
death of dopaminergic neurons in Parkinson’s disease. The toxicity mecha-
nism of a-synuclein oligomers likely involves membrane permeabilization.
Even though it is well established that a-synuclein oligomers bind and per-
meabilize vesicles composed of negatively-charged lipids, little attention has
been given to the interaction of oligomers with bilayers of physiologically
relevant lipid compositions. We investigated the interaction of a-synuclein
with bilayers composed of lipid mixtures that mimic the composition of
plasma and mitochondrial membranes. In the present study, we show that
monomeric and oligomeric a-synuclein bind to these membranes. The
resulting membrane leakage differs from that observed for simple artificial
model bilayers. Although the addition of oligomers to negatively-charged
lipid vesicles displays fast content release in a bulk permeabilization assay,
adding oligomers to vesicles with compositions mimicking mitochondrial
membranes shows a much slower loss of content. Oligomers are unable to
induce leakage in the artificial plasma membranes, even after long-term
incubation. CD experiments indicate that binding to lipid bilayers initially
induces conformational changes in both oligomeric and monomeric a-syn-
uclein, which show little change upon long-term incubation of oligomers
with membranes. The results of the present study demonstrate that the
mitochondrial model membranes are more vulnerable to permeabilization
by oligomers than model plasma membranes reconstituted from brain-
derived lipids; this preference may imply that increasingly complex mem-
brane components, such as those in the plasma membrane mimic used in
the present study, are less vulnerable to damage by oligomers.
Introduction
Parkinson’s disease (PD) is one of the most common
human neurodegenerative diseases, involving the pro-
gressive loss of dopaminergic neurons in the substantia
nigra in the midbrain [1]. The appearance of Lewy
bodies is characteristic of the pathology of PD. The
main component of these Lewy bodies is the protein
a-synuclein (aS), which is present as amyloid fibrils.
aS comprises a 140 amino acid intrinsically disordered
protein [2–7] of as yet unknown function. In PD,
aggregation of aS causes the protein to lose its puta-
tive function and gain toxicity [8–11]. aS consists of a
positively-charged N-terminal region (residues 1–60)
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containing imperfect KTKEGV repeats, a hydropho-
bic NAC region (residues 61–95) and a negatively-
charged C-terminal region (residues 96–140). For
membrane binding, the N-terminal part of aS plays a
key role. Upon binding to phospholipid membranes,
the protein adopts an a-helical structure [12,13]. Inter-
actions of monomeric aS with lipid vesicles of differ-
ent compositions and size have been reported [14–19].
Current consensus suggests that intermediate species
in the fibril formation pathway of aS are the toxic
species involved in cell death in PD [10,20–22].
Despite structural differences between aS oligomers
and monomers, they both show high affinity for nega-
tively-charged membranes. We have previously shown
that oligomer binding induces leakage of artificial neg-
atively-charged lipid vesicles. Although several studies
[23–25] have shown that isolated oligomers can
decrease the integrity of simple negatively-charged
lipid vesicles, little is known about how these species
bind and permeabilize natural membranes. Mitochon-
drial damage has been observed in PD and mitochon-
drial membranes are therefore considered to be a
likely target for oligomer-induced damage [26–28].
Mitochondrial membranes are enriched in cardiolipin
[29], a unique negatively-charged diphosphatidylglycer-
ol lipid. Monomeric aS shows a high binding affinity
to cardiolipin-containing membranes [30,31]. Quantita-
tive correlation between aS in mitochondria and cyto-
sol confirmed that monomeric aS interacts with
mitochondrial membranes [32]. Moreover, it has been
reported that aS is present on mitochondrial mem-
branes in functional dopaminergic neurons of the
substantia nigra [33,34], where, at physiological con-
centrations, aS is mainly localized at the mitochon-
drial inner membrane and only a small fraction is
found at the outer membrane [32,35]. However, a con-
trasting report suggests that aS is localized in the
outer mitochondrial membrane [27]. Mitochondria of
dopaminergic neurons in brains of PD patients con-
tain a higher concentration of aS than normal brains
[36]. A recent study has suggested that wild-type aS is
mainly localized in mitochondria-associated endoplas-
mic reticulum membranes and modulates the morphol-
ogy of mitochondria [37]. Besides these membranes,
the plasma membrane has been indicated as a site of
oligomer-induced damage. Upon internalization, aS
colocalizes with the inner leaflet of the plasma mem-
brane [38,39]. In a yeast model, it was found that aS
binds to plasma membranes [40]. Finally, a recent
report suggests that aS can interact with lipids in the
plasma membrane, increasing the membrane perme-
ability as a potential mechanism of extracellular neu-
rotoxicity [41].
In the present study, we investigate the binding of
specific, well-characterized, oligomeric aS species to
lipid membranes made of physiologically relevant
mitochondrial and plasma membrane lipid mixtures.
We show that these oligomers cause slow permeabili-
zation of mitochondrial inner membrane mimics,
whereas they bind to (but could not induce leakage in)
plasma membrane inner leaflet model systems.
Results
Binding of aS monomers to bilayers that mimic
the lipid composition of natural membranes
Electrostatic interactions play a key role in binding of
monomers to negatively-charged membranes. Mem-
brane binding of monomers is mainly associated with
positive charges on the N-terminal part of the protein
[19]. Upon binding to negatively-charged lipid bilayers,
monomers adopt an amphipathic a-helical structure.
Fluorescently labeled monomers colocalize with the con-
trol 1,2-dioleoylphosphatidylglycerol (DOPG) vesicles
(Fig. 1A) and with giant unilamellar vesicles (GUVs)
composed of both the mitochondrial and plasma mem-
brane mimicking lipid mixtures (Fig. 1B,C). Analysis of
the Alexa 488-fluorescence intensity at GUV membranes
showed that the highest amount of monomers was
bound at DOPG membranes (Fig. 1D). Unexpectedly,
not all brain phosphatidylethanolamine (PS) : brain
phosphatidylethanolamine (PE) : cholesterol vesicles
bound monomers, with approximately 50% of the vesi-
cles not showing any colocalization of labeled mono-
mers and GUVs. It should be noted that only vesicles
that bind aS were taken into account in in Fig. 1D.
CD spectroscopy was used to assess whether binding
of monomers to vesicles of all lipid compositions
resulted in conformational changes in the protein.
Monomers in solution showed CD spectra typical for an
intrinsically disordered protein with a negative peak at
198 nm. As previously reported, aS monomers form an
a-helix upon binding to small unilamellar vesicles
(SUVs) [13,42]. Upon binding membranes mimicking
plasma or mitochondrial lipid compositions, monomers
adopt an a-helical structure that is characterized by two
negative bands at 208 and 222 nm in the CD spectrum.
The a-helical content of the protein upon binding was
estimated from the mean residue ellipticity (MRE) at
222 nm as explained in the Materials and methods.
Binding of monomers to control DOPG vesicles resulted
in an a-helical content of 65.1  1.2%. Monomers
binding to cardiolipin (CL) : 1-palmitoyl-2-oleoylphos-
phatidylethanolamine (POPE) : 1-palmitoyl-2-oleoylp-
hosphatidylcholine (POPC) membranes or membranes
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composed of brain PS : brain PE : cholesterol adopted
a comparable amount of a-helix (59.0  0.4% and
61.1  0.3%, respectively) (Fig. 2). The similarity of
the CD spectra suggests that aS monomers were fully
bound and in a predominantly a-helical conformation
at saturating lipid concentrations for all types of natural
membranes tested. There were no changes in a-helical
content of aS monomers bound to brain PS : brain
PE : cholesterol vesicles when comparing CD spectra
immediately after binding or after 20 h of incubation
(Fig. 2A). CD data points below 205 nm were not taken
into account because of the high noise, likely as a result
of the presence of some other organic compounds in the
lipid mixtures of brain lipids.
Do aS oligomers bind to bilayers mimicking the
lipid composition of natural membranes and
does this binding result in conformational
changes?
We have previously shown that aS oligomers can bind to
lipid membranes composed of negatively-charged lipids
such as DOPG or POPG [43]. The binding of fluores-
cently labeled oligomers to GUVs with a lipid composi-
tion mimicking either negatively-charged, neuronal or
mitochondrial membranes was studied using confocal
microscopy. We observed that oligomers bind to bilayers
mimicking the lipid composition of both the mitochon-
drial inner membrane and the plasma membrane inner
leaflet (Fig. 3B,C). A semi-quantitative comparison of
oligomer membrane binding was carried out in accor-
dance with that used for the monomers. Oligomers
showed comparable binding to DOPG, CL : POPE :
POPC and brain PS : brain PE : cholesterol GUVs
(Fig. 3D). Similar to the results observed for monomer
binding, we also observed that not all brain PS : brain
PE : cholesterol membranes bound oligomers.
We further investigated whether the membrane bind-
ing caused conformational changes in the oligomers
similar to those observed for monomeric aS using CD
spectroscopy. In solution, oligomers showed some b-
sheet conformation (Fig. 4). Binding of oligomers to
vesicles resulted in a small change in protein confor-
mation for both lipid mixtures. Oligomers showed an
increase in a-helical content upon the addition of
SUVs. The a-helical content of the oligomers was
comparable for all lipid membranes studied and did
not change over time. Oligomers bound to brain
PS : brain PE : cholesterol membranes showed similar
CD spectra immediately after the addition of protein
to membranes and after 20 h of incubation (Fig. 4).
We further investigated the membrane disrupting
properties of oligomers by studying the kinetics of
membrane permeabilization using a dye release assay.
A
B
C
D
Fig. 1. Representative confocal microscopy images of DOPE-rhodamine labeled GUVs (red channel) and aS wild-type-140C-A488 monomers
(green channel). Binding of aS monomers to (A) DOPG, (B) CL : POPE : POPC (4 : 3 : 5) and (C) brain PS : brain PE : cholesterol (2 : 5 : 3)
membranes is depicted. (D) Semiquantitative analysis of fluorescently labeled aS bound to vesicles (n = 15). The error bars represent the
SD. Scale bars = 5 lm. The same experimental settings (master gain, digital offset and laser power) were used for all images.
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Kinetics of membrane permeabilization (dye
release assay)
Oligomers have been shown to disrupt membranes
composed of negatively-charged lipid vesicles [23].
After the addition of oligomers to a solution of calce-
in-filled DOPG large unilamellar vesicles (LUVs), a
rapid release of encapsulated dye was observed
(Fig. 5A). We have previously shown that monomers
and fibrils could also cause membrane permeabiliza-
tion of negatively-charged PG vesicles, although much
higher concentrations of the protein are necessary to
achieve comparable leakage [23]. A comparison of the
oligomer-induced leakage kinetics of the dye from
DOPG LUVs with dye encapsulated in vesicles of lipid
bilayers that mimic physiologically relevant membrane
compositions revealed large differences. Although
oligomer binding was observed after 30 min of incuba-
tion, very little oligomer-induced vesicle leakage of
membranes that mimic natural membranes was
observed at these time scales. For LUVs composed of
a mixture of CL : POPE : POPC, a slow dye leakage
was observed, which was still increasing after 18 h
(Fig. 5B). For these LUVs, the oligomer-induced leak-
age was concentration-dependent; higher oligomer con-
centrations showed more leakage. By contrast, even
after 18 h of incubation, oligomer concentrations as
high as 4 lM did not result in more than 2% mem-
brane leakage for bilayers composed of brain PS:brain
PE:cholesterol (Fig. 5C). To obtain a better under-
standing of the observed slow release kinetics, we used
the diffusion equation assuming steady-state release to
fit the data. In the absence of oligomers the change in
concentration, c, of dye in the vesicles was assumed to
follow the expression c = c(0)[1  e(kt)] where the
rate constant is k = Pc 9 A/V, V is the volume of the
vesicle, Pc is the membrane permeability for calcein
and A is the area over which diffusion takes place. To
fit the data in presence of oligomers, we expect the
rate constant to change or more exponents to be
required to better describe the dye release kinetics.
When oligomers were added, fast leakage was
observed for DOPG LUVs. This is not the case for
membranes composed of CL : POPE : POPC. Oligo-
mer-induced leakage from these vesicles required a fit
with at least three exponentials. One of these expo-
nents is comparable for all oligomer concentrations
(the exponent associated with amplitude C in Table 1).
This amplitude (C) decreases with increasing oligomer
concentration and was attributed to the calcein perme-
ability of the bare bilayer. With increasing oligomer
concentration, a decreasing fraction of vesicles is not
affected by oligomers and shows leakage comparable
to bare membranes. From the slow exponent attrib-
uted to the bare membrane, the calcein permeability
Pc of the CL : POPE : POPC membrane was calcu-
lated to be approximately 1013 cms1. The ampli-
tudes of the other two exponents increase with
increasing oligomer concentration, indicating that
these contributions result from the presence of oligo-
mers. Both oligomer-related rate constants were
observed to increase with increasing oligomer concen-
tration (Table 1).
Discussion
It is well established that binding of aS to lipid bilay-
ers is accompanied by an increase in a-helical content
[13]. The binding of aS to lipid bilayers strongly
depends on the presence of negatively-charged lipids
A
B
Fig. 2. CD measurements of conformational changes of aS
monomers (. . .) upon binding to membranes. (A) Binding of aS to
DOPG (–  –), CL : POPE : POPC (. . ..) and brain PS : brain
PE : cholesterol (– –) vesicles showed an increase of a-helical
content. There is no change in a-helical content of aS monomers
bound to brain PS : brain PE : cholesterol vesicles over time when
comparing CD spectra 10 min (– –) after binding or after 20 h of
incubation (–). (B) Percentage of a-helix formed for aS monomers
bound to vesicles with the lipid compositions tested above. Data
are the mean of three different measurements. Error bars
represent the SD.
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[13,14,19,44–46]. However, although most studies sug-
gest that neutral membranes do not bind aS [13,47],
other studies claim differently [14,48]. The amount of
aS bound to lipid bilayers is proportional to the
number of available binding sites and therefore to the
fraction of negatively-charged lipids in the bilayer
[14,19]. Earlier studies with brain-derived lipids
showed no binding of aS to lipid bilayers that con-
tained only 10–15% of PS lipids, indicating that the
20% used in the present study is close to the minimal
amount required for aS binding [13]. Variations in
composition of the brain PS : brain PE : cholesterol
GUVs may explain why monomers did not bind to all
brain PS : brain PE : cholesterol GUVs. This varia-
tion in composition is possibly caused by the presence
of brain PS in the lipid mixture. It has been suggested
that brain PS can interfere with the electroformation
of GUVs resulting in variation in lipid composition of
the resulting vesicles [49].
In the presence of excess vesicles of all lipid com-
positions (DOPG or natural lipids), aS showed com-
parable results in CD binding studies. The maximal
a-helical content of the protein did not depend on
the negatively-charged lipid species. Interactions of
CL containing vesicles with aS monomers have been
characterized by 19F-NMR [31]. It was proposed that
the positively-charged N-terminal region is involved
in binding via an interaction between positively-
charged lysines and negatively-charged CL [31]. The
protein binds to lipid surfaces through an amphi-
pathic a-helix adopted by 100 amino acid residues on
the N-terminal part of the protein, whereas the acidic
A
B
C
D
Fig. 3. Representative confocal microscopy images of DOPE-rhodamine labeled GUVs (red channel) and aS wild-type-140C-A488 oligomers
(green channel). Binding of aS oligomers to (A) DOPG, (B) CL : POPE : POPC and (C) brain PS : brain PE : cholesterol vesicles is depicted.
(D) Semiquantitative analysis of fluorescently labeled oligomers bound to vesicles (n = 15). The error bars represent the SD. Scale
bars = 5 lm. The same experimental settings (master gain, digital offset and laser power) were used for all images.
Fig. 4. CD measurements of conformational changes of aS
oligomers upon binding to membranes. Oligomers partially adopted
a-helical structure upon the addition of SUVs. No difference in
changes of protein conformation was observed after 20 h for aS
oligomers binding to brain PS : brain PE : cholesterol vesicles. aS
oligomers (. . .), DOPG (–  –), CL : POPE : POPC (. . ..) and brain
PS : brain PE : cholesterol after 10 min (– –) and 20 h of
incubation (–).
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C-terminal tail of the protein remains in solution [2].
According to the literature, aS monomers adopt 41%
a-helix in the presence of 1 mM SDS [50], whereas,
upon binding to DPPC : DPPG vesicles, 61% of the
protein adopted the a-helical conformation [51],
which is comparable to the observations reported in
the present study.
Similar to aS monomers, oligomers were found to
bind lipid bilayers of all compositions studied. How-
ever, compared to observations on aS monomers, the
helical content observed in the presence of oligomers
was much lower [23]. It is possible that only the mono-
mers in the oligomer facing the bilayer bind the mem-
brane and adopt an a-helical conformation.
Alternatively, the interactions between aS monomers
in the oligomer may be too strong to permit further
conformational changes upon lipid binding.
Oligomers interacting with simple negatively-
charged lipid bilayers composed of, for example,
DOPG or POPG immediately permeabilize these lipid
membranes [25]. Fast content release was also
observed for vesicles containing POPC : DOPA lipids
[23,43]. The binding of oligomers to lipid bilayers has
been reported to not always result in membrane per-
meabilization [23,25]. Even 30 min after the addition
of the oligomers, POPG : POPC bilayers remained
intact [43,52]. For the two-component lipid mixture
CL : POPC (1 : 3), a lipid composition that comes
close to that of mitochondrial membranes, no leakage
was observed over short time scales [23]. In the pres-
ent study, we show that the interaction of oligomers
with bilayers does not necessarily result in a fast loss
of membrane integrity. Membranes with a lipid com-
position [CL : POPE : POPC (4 : 3 : 5)] similar to
that reported earlier [23] show some dye release over
18 h (Fig. 5B). However, even over these long time
scales, oligomer binding did not result in permeabili-
zation of the plasma membrane mimicking lipid
bilayers (brain PS : brain PE : cholesterol) (Fig. 5C).
To describe the oligomer-induced calcein release
kinetics from CL : POPE : POPC vesicles, at least
three exponentials, and therefore at least three rate
constants, were necessary. The presence of more than
one rate constant suggests that subpopulations of ves-
icles are differently affected by the addition of oligo-
mers. The value of one of the rate constants (k3 in
Table 1) describing the calcein flux as a function of
oligomer concentration is comparable to that
observed for lipid bilayers in the absence of oligomers
[53,54]. This suggests that a fraction of the vesicles is
not affected by the oligomers. Oligomers either did
not bind or did not affect the calcein permeability of
this fraction. As expected, the fraction of unaffected
vesicles becomes smaller with an increasing oligomer
concentration. The amplitude of the other two expo-
nents increases with the oligomer concentration. The
dye release kinetics described by these two exponents
is therefore attributed to the presence of oligomers in
A
B
C
Fig. 5. Dye release kinetics from vesicles of different lipid
composition after the addition of aS oligomers. (A) with DOPG
vesicles 1 lM oligomers showed almost complete leakage and fast
kinetics, which reached a plateau after 12 min. (B) CL:POPE:POPC
vesicles did not result in comparable leakage after 18 h, even with
4 lM oligomer concentration. (C) Oligomers did not induce
appreciable leakage in brain PS : brain PE : cholesterol model
membranes, even over a long time scale. 4 lM oligomers (– – –),
1 lM oligomers (- - -), 0.5 lM oligomers (–  –) and lipids alone (- - -).
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or on the lipid bilayer. Unexpectedly, both rate
constants are observed to increase with increasing oli-
gomer concentrations (Table 1). The oligomer-depen-
dent exponents are expected to contain contributions
of both the lipid bilayer and the oligomers. Because
the leakage is much faster in the presence of oligo-
mers, we assume that the contribution of oligomers is
very large compared to the contribution of the bare
bilayer. As indicated in the Results, the value of k
depends not only on the permeability coefficient P,
but also on the volume of the vesicle and the area
over which diffusion takes place. With increasing
oligomer concentrations, the area covered by
oligomers is expected to become larger. In contrast to
our observation, this increase in oligomer area should
give rise to an increase in the rate constants
contributed to oligomers. The observed decrease in
the rate constants may result from an increase in ves-
icle volume (i.e. by incorporation of oligomers in the
lipid bilayer). Dynamic light scattering experiments
indicate that CL : POPE : POPC LUVs indeed
become larger upon incubation with oligomers, sup-
porting the hypothesis that the decrease in rate
constants corresponding to oligomer-induced leakage
results from a volume increase. The observed change
in the CL : POPE : POPC vesicle diameter of
approximately 30 nm corresponds to the expected
volume change resulting from oligomer incorporation
(Fig. 6). The decrease in leakage observed for brain
PS : brain PE : cholesterol bilayers in the presence of
oligomers possibly results from the binding of
oligomers and blocking of the membrane surface.
The permeability of the oligomer-covered surface is
low compared to the permeability of the bare mem-
brane surface.
Recent data on more physiologically relevant brain
total lipid extract membranes (BTLEMs) have shown
that aS causes bilayer defects [55]. We speculate that
the brain PS : brain PE : cholesterol model system
that we use may show a lipid rearrangement similar
to that proposed for BTLEMs. Cholesterol in com-
plex model brain PS : brain PE : cholesterol mem-
branes can have an additional stabilizing effect on
these membranes [23,43,48,56], making them less vul-
nerable to oligomer-induced leakage. In our experi-
mental system, the inclusion of cholesterol at a
constant charge density does not appear to have any
appreciable effect on the extent of permeabilization
(Fig. 7). However, it has been suggested that the
amount of cholesterol in the plasma membrane is
important for the formation of amyloid channels
[57,58].
Table 1. Fitting parameters for oligomer-induced calcein leakage from CL:POPE:POPC vesicles. Fits were determined using
y ¼ A ð1 ek1tÞ þ B  ð1 ek2tÞ þ C  ð1 ek3tÞ þ y0. A and B, pre-exponential factors associated with oligomer-induced leakage;
k1 and k2, rate constant of oligomer-induced leakage; C, pre-exponental factor of bare membrane leakage; k3, rate constant bare vesicle
leakage; y0, the offset. We present calcein release kinetics measured for six different oligomer concentrations: 4, 3, 2, 1, 0.5 and 0.25 lM.
At least three exponentials were necessary for adequate fits of our data.
Concentration (lM) A B C k1 (h
1) k2 (h
1) k3 (h
1)
4 6.4  0.17 7.8  0.13 86 10.87  0.59 0.47  0.02 0.004
3 6.33  0.14 7.39  0.12 86 10.15  0.47 0.45  0.02 0.004
2 5.8  0.1 7.5  0.08 85.5 12.59  0.47 0.47  0.012 0.004
1 2.87  0.06 4.79  0.07 92 10.58  0.48 0.34  0.01 0.002
0.5 2.69  0.04 2.69  0.07 94.03 13.88  0.47 0.31  0.01 0.001
0.25 2.52  0.04 1.31  0.03 96.4 13.28  0.4 0.37  0.03 < 0.001
Fig. 6. Typical dynamic light scattering graph for
CL : POPE : POPC LUVs before and after the addition of
oligomers. Parameters from dynamic light scattering
measurements are described as the volume of particles (%) as a
function of size (nm) [F(size, nm) = volume of vessicles, %] for
vesicles alone [CL : POPE : POPC (–)] and vesicles + oligomers
(– – –). Changes in diameter between membranes (144.1  6.0)
and membranes after the addition of oligomers (177.8  15.1) are
approximately 30 nm for CL : POPE : POPC membranes. Peak
width changes were approximately 12 nm; peak width of vesicles
alone is 50.2  6.5 nm and peak width after 18 h of incubation
with oligomers is 62.6  4.5 nm.
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For the amyloid-forming protein islet amyloid poly-
peptide, slow dye release from POPG : POPC vesicles
was concluded to be caused by the formation of fibrils
[59]. The experiments reported in the present study
were performed with stable oligomers [60]. Thus, we
do not expect that conformational changes and further
aggregation play a role in long-term leakage kinetics.
Alternatively, any conformational changes in the oligo-
mer may be beyond our detection limit because they
involve only a few proteins.
The reported membrane leakage data suggest that
complex lipid membranes are less prone to oligomer-
induced damage. The complexity of model plasma
membranes lies in the composition of the membranes
itself, which consist largely of combinations of long
and polyunsaturated lipids in the brain lipid extracts
used. The results of the present study show that mito-
chondrial model membranes are more prone to oligo-
mer-induced damage over longer time scales, whereas
the more complex plasma membrane model systems
do not show a concentration-dependent permeabiliza-
tion over the same time scale. Other in vitro studies
have suggested that the mitochondria specific lipid CL
is essential for aS mitochondrial membrane interac-
tions [46]. A recent study [61] confirmed a common
mechanism of damage for mitochondrial membranes
by amyloid-induced species via direct interactions of
these species with membrane phospholipids. Their pro-
posed mechanism agrees very well with our data on
mitochondrial model membranes, which is mediated
by the increased affinity of these species for CL.
Materials and methods
Expression and purification of aS
Expression and purification of human wild-type aS and the
cysteine (Cys) mutant aS-A140C, where alanine at position
140 was replaced with a cysteine, was carried out as
described previously [62]. The protein concentration was
determined by measuring the absorbance on a spectropho-
tometer at 276 nm, using molar extinction coefficients of
5600 M1cm1 for wild-type and 5745 M1cm1 for A140C
[60,63]. The protein was stored at 80 °C until further use.
Labeling of aS
The Cys mutant aS-A140C was used for labeling the pro-
tein with an Alexa Fluor 488 C5 maleimide dye (A488) (In-
vitrogen, Carlsbad, CA, USA). Prior to labeling, a six-fold
molar excess of dithiothreitol was added to aS-A140C to
reduce disulfide bonds. After 30 min of incubation, dith-
iothreitol was removed using Zeba Spin desalting columns
(Pierce, Rockford, IL, USA) and a two-fold excess of A488
was added. After 1 h of incubation, excess of free dye was
removed using two desalting steps. The labeling efficiency
was estimated to be in the range 90–100% from absorption
spectra. To determine the protein and A488 concentration
the absorbance at 276 nm was measured using a molar
extinction coefficient of 5745 M1cm1 for the protein and
at 495 nm using a molar extinction coefficient of
72 000 M1cm1 for the dye.
Preparation of unlabeled and labeled
aS oligomers
Briefly, oligomers were obtained by incubating aS at high
concentrations in the absence of additional factors [23].
Alexa 488 labeled oligomers with 7.5% labeling density,
achieved by mixing appropriate quantities of labeled protein
(aS-A140C) with unlabeled protein (wild-type), were pre-
pared for membrane binding studies by confocal microscopy.
Oligomers were purified and separated from monomers using
size-exclusion chromatography on a SuperdexTM 200 10/300
GL column (GE Healthcare Bio-Sciences AB, Uppsala, Swe-
den). Separation of oligomers from monomers is based on
size, where larger particles (oligomers) elute first. To confirm
the presence of oligomers, a native PAGE gradient gel was
used [23] with a polyacrylamide gradient of between 3% and
16%. We have previously demonstrated that oligomers pre-
pared in this manner are composed of approximately 30
monomers, and are stable [60]. Monomers could not be
detected in the oligomer preparation (data not shown).
Fig. 7. Oligomer-induced leakage kinetics from vesicles of different
lipid composition: DOPG : DOPC (1 : 2, black circles),
DOPG : DOPC (1 : 4, grey triangles), DOPG : DOPC:cholesterol
(2 : 5 : 3, blue pentagons) and DOPG : DOPC : cholesterol
(4 : 3 : 5, red circles). Oligomers at 1 lM (equivalent monomer)
concentration were incubated with the lipid membranes for 18 h.
Oligomer-induced leakage was < 5%, which is comparable to the
data observed with our plasma inner leaflet membrane mimics.
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LUV preparation and calcein release assay
All lipids were purchased from Avanti Polar Lipids (Ala-
baster, AL, USA). In the experiments the lipids used were:
POPC, DOPG, POPE, 10,30-bis[1,2-dioleoyl-sn-glycero-3-
phospho]-sn-glycerol (18 : 1 CL), porcine brain L-a-phos-
phatidylserine (brain PS), porcine brain L-a-phosphatidyl-
ethanolamine (brain PE) and cholesterol.
To mimic the lipid composition of neuronal plasma
membranes, we used mixtures of brain PS : brain PE : cho-
lesterol in a molar ratio of 2 : 5 : 3, which corresponds to
20% of negatively-charged lipids. However, no elaborate
data of brain lipid compositions are available. The neuro-
nal membrane has approximately 10% negatively-charged
lipids, mainly PS, whereas the main components of these
membranes are neutral PC and PE phospholipids [64].
However, this estimation of the lipid composition does not
take into account asymmetry between the inner and outer
leaflets of the membrane [13]. Because aS is an intracellular
protein, we chose to the mimic the inner leaflet of the
plasma membrane, which is enriched in PS. aS has also
been implicated in interactions with mitochondrial mem-
branes. Data from the literature suggest that aS preferen-
tially binds to the mitochondrial inner membrane [29]. To
mimic the mitochondrial inner membrane, we used a lipid
composition that contains CL : POPE : POPC in a molar
ratio 4 : 3 : 5 [29].
Specific lipid compositions were prepared by mixing
650 lM of lipids in chloroform. The solvent was removed
by drying under nitrogen flow. The resulting lipid films
were then hydrated for 1 h using 50 mM calcein, 10 mM
Hepes and 60 mM NaCl to obtain an osmolality (Cryo-
scopic osmometer; Gonotec, Berlin, Germany) of
320 mOsmkg1. The sample was then subjected to five
freeze–thaw cycles using liquid nitrogen and a water bath.
The temperature of the water bath was kept above the
transition temperature of the lipid mixture. The solution
was subsequently extruded 11 times through 100-nm pore
size filters (Whatman, Maidstone, UK) and finally unen-
capsulated calcein was removed using PD-10 columns filled
with Sephadex G-100 (GE Healthcare Bio-Sciences AB).
Long-term calcein release kinetics of the model mem-
branes was followed on a Varian Cary Eclipse fluorometer
(Varian Inc., Palo Alto, CA, USA). We used lipid concen-
trations of 40 lM. The emission intensity was recorded at
515 nm for excitation at 495 nm. Triton X (0.5%) was
added to completely lyse the vesicles. All the data points
were normalized using the intensity after Triton X treat-
ment as 100% leakage.
Semi-quantitative aS monomer and oligomer
binding assay
GUVs were prepared in sucrose solution as described previ-
ously by Angelova and Dimitrov [65]. The sucrose concen-
tration was equiosmolar to the 10 mM Hepes, 150 mM
NaCl solution in which the proteins were dissolved. 1%
DOPE-rhodamine was included in the lipid mixtures to
facilitate visualization of the lipid membrane.
GUVs mimicking natural lipid compositions were equili-
brated with fluorescently labeled oligomers for 30 min
before imaging. DOPG vesicles were used as a positive con-
trol for binding of monomers and oligomers to membranes.
The experiments were performed using the same experi-
mental settings (master gain, digital offset and laser power)
for imaging the binding of both monomers (Fig. 1) and
oligomers (Fig. 3). DOPE-rhodamine was excited with a
He/Ne laser (543 nm) and Alexa 488 was excited with an
Argon laser (488 nm) on a CLSM 510 confocal microscope
(Carl Zeiss, Oberkochen, Germany). We used the script plot
profile in IMAGEJ (NIH, Bethesda, MD, USA) to extract
semi-quantitative fluorescence values reporting on the bind-
ing of monomers and oligomers to membranes. The
amount of aS bound to GUV membranes was estimated
from the peak values of the Alexa 488 intensity profiles and
averaged for at least 15 vesicles on five random cross-sec-
tions using the same imaging settings (master gain, digital
offset and laser power). Figures 1A–C and 3A–C show rep-
resentative confocal images of the binding of fluorescently
labeled aS monomers (Fig. 1) and oligomers (Fig. 3).
SUVs preparation and binding of aS oligomers to
SUVs
Lipid mixtures that contain 3.8 mM of lipids in chloroform
were prepared. After removing traces of chloroform, a thin
lipid film was dissolved in 10 mM K-phosphate buffer.
SUVs were prepared from this solution by sonicating for
30 min using a tip sonicator (Labsonic, Branson Ultraso-
nics, Danbury, CT, USA) at maximum amplitude on ice.
Binding-induced conformational changes of oligomeric and
monomeric aS were investigated using CD spectroscopy
[66]. Both protein and lipids samples were prepared in
10 mM K-phosphate buffer. Spectra were recorded using a
Jasco 715 spectropolarimeter (Jasco Inc., Easton, MD,
USA) in the range 190–260 nm with a step size of 0.2 nm,
band width 2 nm and scanning speed 50 nmmin1 in 1-
mm quartz cuvettes. The spectra represent the mean of
three scans and were corrected for the background from
K-phosphate buffer and aS-free vesicles. Monomer and oli-
gomer concentrations were 16 and 10 lM of equivalent
monomer concentration, respectively, keeping the lipid to
protein ratio 260 : 1 for oligomers binding to SUVs and
170 : 1 for monomers binding to SUVs. A lipid concentra-
tion of 2.72 mM resulted in the above-mentioned lipid to
protein ratio. These ratios were chosen to obtain complete
binding of the protein [13,42]. MREs (degdmol1cm2)
were calculated using Eqn (1), where c is the protein con-
centration, l is the pathlength cuvette and nresidues is the
number of residues (amino acids):
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MRE ¼ recorded value buffer value
lðcmÞ  nresidues  10 cðMÞ ð1Þ
In principle, the MRE at any wavelength is a combina-
tion of a-helical structure, b-sheet and random coil content
of the sample [67]. The a-helical content was estimated by
measuring the CD signal at 222 nm; at this wavelength, the
contribution of random coil structure is relatively small
[68].
At 222 nm, the a-helical content was obtained using
Eqns (2, 3, 4):
%helicity ¼ h222  hcoil
hhelix  hcoil  100 ð2Þ
where hhelix and hcoil could be calculated:
hcoil ¼ 640 45 # ð3Þ
hhelix ¼ 4000 1 2:5
n
 
þ 100 # ð4Þ
where Θ222 is the measured mean residue ellipticity at
222 nm, hhelix and hcoil are mean residue ellipticities at
222 nm of idealized a-helix and random coil proteins,
n = 140 amino acids and ϑ is the temperature (°C).
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